Olema Oncology's Inducement Grants for Employees
Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", NASDAQ: OLMA) has recently reported the granting of stock options to four new employees, reflecting its commitment to build a robust team in the ongoing fight against breast cancer. This move is part of Olema's 2022 Inducement Plan and is aligned with Nasdaq Listing Rule 5635(c)(4).
Details on Stock Options Granted
The total number of stock options granted amounts to 154,500 shares of the company's common stock. These options were effective as of July 1, 2025. The company designed the options to vest over a period of four years, ensuring new employees are invested in the company's future success. Notably, 25 percent of the options will vest on the first anniversary, with the remainder of the shares vesting in 36 equal monthly installments thereafter, provided the employees remain with the company throughout the vesting period.
Exercise Price and Term of Options
The exercise price for these options has been set at $4.37 per share, which corresponds to the last reported sale price as recorded by Nasdaq at the time of the grant. Each option will have a term of ten years from the date of grant, offering employees a significant opportunity to participate in the company's growth and development.
Commitment to Breast Cancer Treatment
Olema Oncology is at the forefront of transforming breast cancer care through its innovative therapeutic approaches. The company is dedicated to enhancing the standard of care for patients by advancing its pipeline of targeted therapies. One of its significant product candidates, palazestrant (OP-1250), is currently undergoing a Phase 3 clinical trial, known as OPERA-01, illustrating Olema's commitment to developing effective treatments for breast cancer.
Research and Development Initiatives
In addition to palazestrant, Olema is also engaged in developing OP-3136, a potent inhibitor aimed at targeting lysine acetyltransferase 6 (KAT6). This initiative is moving forward in a Phase 1 clinical trial. With operations based in San Francisco and Cambridge, Massachusetts, Olema is focused on leveraging its expertise to develop novel therapies that can address the complex challenges posed by endocrine-driven cancers.
About Olema Oncology
Headquartered in San Francisco, Olema Oncology is dedicated to improving patient outcomes through the innovative treatment of breast cancer. The investments in its employee stock options reflect the company's belief in its talented workforce as it continues to evolve within the biopharmaceutical landscape. For further information, please visit www.olema.com.
Media and Investor Relations
For any media inquiries, please reach out to: Courtney O'Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
Frequently Asked Questions
What are the stock options granted by Olema Oncology?
Olema Oncology granted stock options to four new employees, totaling 154,500 shares, under its 2022 Inducement Plan.
What is the duration of the stock options?
The stock options have a 10-year term, giving employees a long duration to capitalize on their investments in the company.
When do the stock options vest?
The options vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly over the following three years.
What is Olema's focus in the biopharmaceutical industry?
Olema is focused on the development of targeted therapies for breast cancer and endocrine-driven cancers.
Who can I contact for more information about Olema Oncology?
You can contact Courtney O'Konek, the Vice President of Corporate Communications, at media@olema.com for more information.
